Peptide-Based Imaging Probe Successfully Detects HER2-Positive Tumors in Mice

What the researchers found

The 99mTc-peptide-ZHER2:342 molecular probe was successfully synthesized and labeled with technetium-99m at 98.10 ± 1.73% efficiency. The probe remained highly stable in vitro and showed clear selective imaging: HER2-expressing SKOV-3 tumor xenografts showed high uptake and were clearly visible, while HER2-low MDA-MB-231 xenografts were not detectable at any time point after injection.

The predominant clearance pathway was renal (through the kidneys), which is favorable for imaging because it reduces background signal in the abdomen and allows cleaner tumor visualization.

Why it matters

Knowing whether a tumor is HER2-positive is critical for selecting the right cancer treatment, but current methods typically require a tissue biopsy. A non-invasive imaging probe that can detect HER2 status throughout the body could revolutionize cancer diagnosis and treatment monitoring — allowing doctors to see HER2 expression in real time without surgery, and potentially detecting metastases that biopsies would miss.

How the study worked

The ZHER2:342 Affibody molecule was synthesized using solid-phase peptide synthesis (Fmoc/tBu chemistry). A chelating peptide sequence (Gly-(d)Ala-Gly-Gly) was attached to enable technetium-99m labeling. Labeling efficiency and stability were assessed by reversed-phase HPLC. Biodistribution and imaging studies were performed in nude mice bearing either HER2-positive (SKOV-3) or HER2-negative (MDA-MB-231) tumor xenografts.

What this study cannot tell us

This is a preclinical study in nude mice with implanted human tumor xenografts, which does not fully replicate human cancer biology. Only two cell lines were tested (one HER2-positive, one HER2-negative). The study did not assess imaging in the presence of more complex anatomical structures or in larger animals. Translation to human clinical use would require extensive further development including toxicity studies and regulatory approval.

How to read the evidence

This is an early-stage preclinical study demonstrating proof-of-concept in mouse tumor models. While the results are promising, this represents the initial development phase of a diagnostic agent with no human data.

When this study was published

Published in 2014, this study contributed to the growing field of affibody-based molecular imaging. Since then, several peptide and affibody-based imaging agents have advanced further toward clinical development.

The bigger picture

Affibody molecules represent a class of engineered peptide-based binding proteins that are much smaller than antibodies, giving them advantages for molecular imaging including faster tumor penetration, quicker blood clearance, and higher contrast images. This work contributes to the broader development of peptide-based diagnostics that could complement or replace antibody-based approaches for cancer detection and monitoring.

Questions still open

• Could this peptide-based probe be used to monitor changes in HER2 expression during cancer treatment without repeated biopsies?
• How does the imaging quality compare to existing HER2 detection methods like immunohistochemistry or FISH testing?
• Would this probe work with other radioisotopes or imaging modalities like PET scanning for higher resolution?

Common questions

Read the original research

Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.

The British journal of radiology, 87(1033), 20130484

Citation

Zhang, J-M; Zhao, X-M; Wang, S-J; Ren, X-C; Wang, N; Han, J-Y; Jia, L-Z. (2014). Evaluation of 99mTc-peptide-ZHER2:342 Affibody® molecule for in vivo molecular imaging.. The British journal of radiology, 87(1033), 20130484. https://doi.org/10.1259/bjr.20130484